M&A Deal Summary |
|
|---|---|
| Date | 2023-08-01 |
| Target | EQRx |
| Sector | Life Science |
| Buyer(s) | Revolution Medicines |
| Deal Type | Add-on Acquisition |
| Advisor(s) | Goldman Sachs MTS Health Partners (Financial) Goodwin Procter (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2014 |
| Sector | Life Science |
| Employees | 616 |
| Revenue | 11M USD (2023) |
Revolution Medicines is a developer of new drugs directed toward frontier oncology targets for cancer patients. Frontier targets include proteins that drive the growth and survival of cancer but carry a typical structural or regulatory features requiring unconventional drug discovery strategies. Revolution Medicines was founded in 2014 and is based in Redwood City, California.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Add-on Acquisition M&A Deals | 2 of 2 |
| State: Massachusetts M&A | 2 of 2 |
| Country: United States M&A | 2 of 2 |
| Year: 2023 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-10-16 |
Warp Drive Bio
Cambridge, Massachusetts, United States Warp Drive Bio, Inc. is a developer of drug modality (SMART™) based on the molecular design and optimization of compounds to engage surfaces on disease-causing proteins that were previously viewed as undruggable. Warp Drive Bio, Inc. is based in Cambridge, Massachusetts. |
Buy | - |
